Log in

NASDAQ:BLCMBellicum Pharmaceuticals Stock Price, Forecast & News

$8.78
-0.12 (-1.35 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.60
Now: $8.78
$9.56
50-Day Range
$4.56
MA: $6.54
$8.72
52-Week Range
$3.32
Now: $8.78
$27.90
Volume77,464 shs
Average Volume125,821 shs
Market Capitalization$44.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.18
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Read More
Bellicum Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLCM
CUSIPN/A
Phone832-384-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.14 million
Book Value($5.25) per share

Profitability

Net Income$-112,480,000.00
Net Margins-1,574.65%

Miscellaneous

Employees173
Market Cap$44.34 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.

Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

How has Bellicum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLCM stock has increased by 20.4% and is now trading at $8.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bellicum Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellicum Pharmaceuticals.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Bellicum Pharmaceuticals.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, beating the Zacks' consensus estimate of ($2.73) by $3.82. Bellicum Pharmaceuticals had a negative return on equity of 664.19% and a negative net margin of 1,574.65%. View Bellicum Pharmaceuticals' earnings history.

When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work?

Bellicum Pharmaceuticals's stock reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BLCM?

1 brokerages have issued 1 year target prices for Bellicum Pharmaceuticals' shares. Their forecasts range from $17.00 to $18.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $17.50 in the next year. This suggests a possible upside of 99.3% from the stock's current price. View analysts' price targets for Bellicum Pharmaceuticals.

Has Bellicum Pharmaceuticals been receiving favorable news coverage?

Headlines about BLCM stock have been trending positive on Saturday, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bellicum Pharmaceuticals earned a news sentiment score of 2.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBellicum Pharmaceuticals.

Are investors shorting Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 400,200 shares, a decline of 5.3% from the April 30th total of 422,800 shares. Based on an average trading volume of 130,000 shares, the short-interest ratio is currently 3.1 days. Currently, 8.1% of the shares of the company are short sold. View Bellicum Pharmaceuticals' Current Options Chain.

Who are some of Bellicum Pharmaceuticals' key competitors?

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the following people:
  • Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
  • Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
  • Mr. Thomas J. Farrell, Consultant (Age 56)
  • Mr. Atabak Mokari, Chief Financial Officer (Age 42)
  • Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Who are Bellicum Pharmaceuticals' major shareholders?

Bellicum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (4.31%), Sumitomo Mitsui Trust Holdings Inc. (4.31%), Nikko Asset Management Americas Inc. (4.31%), Frazier Management LLC (2.08%), BlackRock Inc. (2.00%) and Morgan Stanley (0.49%). Company insiders that own Bellicum Pharmaceuticals stock include David M Spencer, Jon P Stonehouse, Richard A Fair and Shane Ward. View institutional ownership trends for Bellicum Pharmaceuticals.

Which institutional investors are selling Bellicum Pharmaceuticals stock?

BLCM stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Frazier Management LLC, BlackRock Inc., Wells Fargo & Company MN, X Square Capital LLC, and Shufro Rose & Co. LLC. View insider buying and selling activity for Bellicum Pharmaceuticals.

Which institutional investors are buying Bellicum Pharmaceuticals stock?

BLCM stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, and Tower Research Capital LLC TRC . Company insiders that have bought Bellicum Pharmaceuticals stock in the last two years include Jon P Stonehouse, Richard A Fair, and Shane Ward. View insider buying and selling activity for Bellicum Pharmaceuticals.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $8.78.

How big of a company is Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals has a market capitalization of $44.34 million and generates $7.14 million in revenue each year. The biopharmaceutical company earns $-112,480,000.00 in net income (profit) each year or ($19.91) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.

What is Bellicum Pharmaceuticals' official website?

The official website for Bellicum Pharmaceuticals is www.bellicum.com.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.